Immuneering reports Q2 2026 results, MAPKeeper 301 dosing underway
The company reported 17.3 month median overall survival in a first-line pancreatic cancer study and said its Phase 3 trial has begun dosing patients, with cash extending into 2029.
Immuneering Corporation announced that in June it had dosed the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib plus mGnP in first-line metastatic pancreatic cancer patients.1 The company said over 30 study locations for the trial have been posted to date.1
At the ASCO Annual Meeting on June 1, the company presented Phase 2a data showing 17.3 month median overall survival and a favorable tolerability profile in 55 first-line pancreatic cancer patients, with 84% of evaluable patients weight stable or gaining weight at 3 months.1 The Phase 2a trial evaluated atebimetinib in combination with mGnP, with results reported as of an April 24, 2026 data cutoff.1
In July, Immuneering said it published an article in Cancer Research characterizing atebimetinib's mechanism, reporting broad antitumor activity across RAS- and RAF-mutant models while resisting RAF-mediated bypass signaling associated with resistance to other MEK inhibitors.1
Looking ahead, the company said it expects to dose the first patient in a Phase 2 trial of atebimetinib plus cemiplimab in non-small cell lung cancer in the second half of 2026, with a preliminary data readout expected in late 2027,1 and to report topline data from MAPKeeper 301 in mid-2028.1
On finances, the company reported cash, cash equivalents and marketable securities of $182.7 million as of June 30, 2026, down from $217.0 million at year-end 2025.1 It said based on this position and current operating plans, it expects its cash runway to fund operations into 2029.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.